Defining the Scope of Eligibility for Concurrent Chemoradiation Therapy for NSCLC
Defining the Scope of Eligibility for Concurrent Chemoradiation Therapy for NSCLC
Time Zone:
America/New York GMT -4 summer
Institution:
AstraZeneca
previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES
Moderator:
Speakers:
Theme :
Language:
Parneet Cheema, Anthony Brade
Discuss strategies to optimize multidisciplinary team management of patients in Stage III unresectable NSCLC, Review the clinical rationale for curative intent concurrent chemoradiation therapy in patients with stage III unresectable NSCLC, Identify patients with stage III, unresectable NSCLC who are candidates for concurrent chemoradiation therapy with a focus on patients with comorbidities
Inglês

LEARNING OBJECTIVES:

1. Discuss strategies to optimize multidisciplinary team management of patients in Stage III unresectable NSCLC

2. Review the clinical rationale for curative intent concurrent chemoradiation therapy in patients with stage III unresectable NSCLC

3. Identify patients with stage III, unresectable NSCLC who are candidates for concurrent chemoradiation therapy with a focus on patients with comorbidities

 

TIME:Tuesday, September 15, 2020 2:00 PM EDT / 11:00 AM PDT

 

SPEAKER:Dr. Parneet Cheema and Dr. Anthony Brade

 

This webinar has been made possible through sponsorship from AstraZeneca

Download the Agenda

Search for our next event. See you soon!

Subscribe to get news on all upcoming events

who%20goals_edited.png

DocMeeetings

Social Media

  • Twitter DocMeetings
  • Instagram DocMeetings
  • Facebook ícone social
  • LinkedIn ícone social

contact us

Adress

Sao Paulo, SP - Brazil

© 2020 by Docmeetings - A DocMeetings.com Company
Site Managed by:
QUALITY Soluções Web
1996-2020 "24 years inspiring technology"